Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group

Abstract

In this observational study, PI/r-containing regimens showed superior efficacy over triple NRTI regimens as first-line therapy in HIV-2-infected patients.

Antiretroviral Therapy and Drug Resistance in HIV-2 Infection

“…Of note, there was no difference in baseline CD4-cell count depending on HIV type. Other non-comparative studies have reported a poor immunological response whatever the antiretroviral regimen tested, triple NRTI or a PI combination (Matheron et al 2006;Benard et al 2009Benard et al , 2011). This dramatic difference in response to cART could be explained by the delay in giving therapy to these infected patients: the longer infection time before experiencing a decrease in CD4 compared to those infected by HIV-1 suggests that earlier treatment is needed, even if the ability of the antiretroviral drugs to reduce plasma HIV-2 RNA seems limited.…”

Update on HIV-1 and HIV-2 Dual Infection

“…To date tuberculosis programs provide only rifampicin in most resource-limited settings (RLS). A less than optimal regimen in dually infected patients with TB coinfection in RLS is a 3 NRTI-regimen; however, failure rates in mono-HIV-1 infection are high, and in HIV-2, 3 NRTIs are less potent below 200 CD4 cells/mm 3 and the higher failure rate reported comparing to PIs boosting regimen (Benard et al 2011). The main limitation of an INI regimen is the cost 7-10 as high as 3 NRTI regimens.…”

Immunologic response in treatment‐naïve HIV‐2‐infected patients: the IeDEA West Africa cohort

“…There have been no randomized trials investigating the response to ART regimens in HIV-2-infected patients [19]. Only a few observational cohort studies with limited sample size have provided information on HIV-2-infected patients on ART in Europe and in the United States [20–26], as well as in West Africa [13–15,27–31]. Moreover, limited data are available on the response to the different first-line regimens used in HIV-2 patients.…”

“…Whereas the data have generally favoured boosted PI regimens over those comprised of triple NRTIs, to our knowledge, only one report from a European collaboration [20] and two from West Africa [15,30] explicitly compared the two first-line regimens. Using data from the International Epidemiological Database to Evaluate AIDS West Africa (IeDEA-WA) HIV-2 collaboration [32], we aimed to investigate the impact of first-line ART regimens on immunological response within the first 12 months of ART, for HIV-2 infected patients in the West Africa region where there are limited options for second-line regimens.…”